Sign inJoin waitlistJoin the waitlist

MT

Mohamed Tejani

Physician · AdventHealth Central Florida Division

Credentials: · · · · ·

History

AdventHealth Central Florida Division
2020–Present

University of Rochester Medicine
2007–2010
Internal Medicine
2004–2007
Geisel School of Medicine at Dartmouth
2000–2004

Research

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised,…
The Lancet Oncology · 2017 · 287 citations
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
The Lancet Oncology · 2023 · 226 citations
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
JAMA Oncology · 2017 · 147 citations

Fergal Fleming
11 papers · 8 as a fellow
Christopher Aquina
9 papers · 8 as a resident
JM
John Monson
9 papers
Supriya Mohile
8 papers
Christian Probst
6 papers
Bradley Hensley
5 papers · 5 as a resident
AJ
Adham Jurdi
4 papers
Diana Hanna
4 papers
Gregory Botta
4 papers
Ronald Epstein
4 papers
Zhaomin Xu
4 papers · 4 as a resident
Aaron Scott
3 papers · 1 as a fellow

Clinical trials

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2027
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Site PI · Recruiting · Phase 2, Phase 3
NRG Oncology
2022–2030
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2021–2027